OBJECTIVE： To observe clinical efficacy and safety of salvianolate in the treatment of acute exacerbation of chronic obstructive pulmonary disease （AECOPD）. METHODS： 80 AECOPD patients were selected and randomly divided into observation group and control group， with 40 cases in each group. Both groups received mechanical ventilation. Control group was given routine treatment of theophyllinum， bronchodilators and glucocorticoid； treatment group was additionally given Salvianolate injection 200 mg，qd，ivgtt， on the basis of control group. Clinical efficacy was observed in 2 groups， blood hemorheology indexes were also observed before and after treatment. The mechanical ventilation time， ICU residence time and ADR were recorded in 2 groups. RESULTS： Clinical total effective rate of observation group was 95.00％， which was significantly higher than 70.00％ of control group， with statistical significance （P＜0.05）. Before treatment and 2 d after treatment， blood rheology indexes of treatment group were improved significantly （all P＞0.05）， and whole blood reduction viscosity of control group was improved significantly （P＜0.05）. Mechanical ventilation time and ICU residence time of treatment group was significantly shorter than that of control group （P＜0.05）. No ADR was found in 2 groups. CONCLUSIONS： Salvianolate can significantly improve the blood coagulation status of AECOPD patients receiving invasive mechanical ventilation， and has the advantages of good clinical efficacy and low cost of medical treatment.